Blake Byers began doing biomedical research as a high school student at Stanford in 2002, and has worked in seven laboratories over the last nine years. Outside of lab, he has worked as a marketer at Electronic Arts, a pharmaceutical equity research analyst at Morgan Stanley, and an angel investor. Blake’s research has spanned antibiotic mechanisms of action, endothelial cell binding, bioimpediance device design, mesendoderm stem cell isolation, Parkinson’s disease modeling, and fMRI imaging of allogeneic brain grafts — resulting in multiple publications and two first author papers (Cell Stem Cell, 2011 and PLoS One, 2011).Blake received a Bachelor of Science in biomedical engineering and Bachelor of Science in economics from Duke University and holds a Master of Science and Ph.D. in bioengineering from Stanford University.
| Date | Company Name | Round | Money Raised | Industry | |
|---|---|---|---|---|---|
| Nov 2, 2022 |
Arta Finance
|
Series A | $90M | Finance | Detail |
| Jul 30, 2021 |
Neuralink
|
Series C | $205M | Hardware | Detail |
| Organization Name | Title At Company | Start Date | End Date | |
|---|---|---|---|---|
Arcus Biosciences
|
Board Observer | Jan 1, 2016 | — | Detail |
PACT Pharma
|
Board Chairman | Jan 1, 2016 | — | Detail |
PACT Pharma
|
President | — | — | Detail |